Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Open questions in oesophageal adenocarcinogenesis.

Literature DB >> 17566022

Open questions in oesophageal adenocarcinogenesis.

Carlo C Maley¹.

Abstract

Entities: Disease

Mesh：

Year: 2007 PMID： 17566022 PMCID： PMC1994388 DOI： 10.1136/gut.2006.117135

Source DB: PubMed Journal: Gut ISSN： 0017-5749 Impact factor: 23.059

× No keyword cloud information.

25 in total

1. Biochemopreventive therapy for patients with premalignant lesions of the head and neck and p53 gene expression.

Authors: D M Shin; L Mao; V M Papadimitrakopoulou; G Clayman; A El-Naggar; H J Shin; J J Lee; J S Lee; A Gillenwater; J Myers; S M Lippman; W N Hittelman; W K Hong
Journal: J Natl Cancer Inst Date: 2000-01-05 Impact factor: 13.506

2. Chromosomal gains and genomic loss of p53 and p16 genes in Barrett's esophagus detected by fluorescence in situ hybridization of cytology specimens.

Authors: Mona Fahmy; Marek Skacel; Terry L Gramlich; Jennifer A Brainard; Thomas W Rice; John R Goldblum; Jason T Connor; Graham Casey; Mona S Legator; Raymond R Tubbs; Gary W Falk
Journal: Mod Pathol Date: 2004-05 Impact factor: 7.842

3. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium.

Authors: D J Wong; T G Paulson; L J Prevo; P C Galipeau; G Longton; P L Blount; B J Reid
Journal: Cancer Res Date: 2001-11-15 Impact factor: 12.701

4. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer.

Authors: S M Lippman; J J Lee; D D Karp; E E Vokes; S E Benner; G E Goodman; F R Khuri; R Marks; R J Winn; W Fry; S L Graziano; D R Gandara; G Okawara; C L Woodhouse; B Williams; C Perez; H W Kim; R Lotan; J A Roth; W K Hong
Journal: J Natl Cancer Inst Date: 2001-04-18 Impact factor: 13.506

5. Discordance between flow cytometric abnormalities and dysplasia in Barrett's esophagus.

Authors: M B Fennerty; R E Sampliner; D Way; R Riddell; K Steinbronn; H S Garewal
Journal: Gastroenterology Date: 1989-10 Impact factor: 22.682

6. Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables.

Authors: P S Rabinovitch; G Longton; P L Blount; D S Levine; B J Reid
Journal: Am J Gastroenterol Date: 2001-11 Impact factor: 10.864

7. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression.

Authors: B J Reid; L J Prevo; P C Galipeau; C A Sanchez; G Longton; D S Levine; P L Blount; P S Rabinovitch
Journal: Am J Gastroenterol Date: 2001-10 Impact factor: 10.864

8. DNA abnormalities as marker of risk for progression of Barrett's esophagus to adenocarcinoma: image cytometric DNA analysis in formalin-fixed tissues.

Authors: Ming Fang; Edward Lew; Michael Klein; Thomas Sebo; Yingyao Su; Raj Goyal
Journal: Am J Gastroenterol Date: 2004-10 Impact factor: 10.864

Open questions in oesophageal adenocarcinogenesis.

1. Biochemopreventive therapy for patients with premalignant lesions of the head and neck and p53 gene expression.

2. Chromosomal gains and genomic loss of p53 and p16 genes in Barrett's esophagus detected by fluorescence in situ hybridization of cytology specimens.

3. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium.

4. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer.

5. Discordance between flow cytometric abnormalities and dysplasia in Barrett's esophagus.

6. Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables.

7. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression.

8. DNA abnormalities as marker of risk for progression of Barrett's esophagus to adenocarcinoma: image cytometric DNA analysis in formalin-fixed tissues.

9. A genetic progression model of oral cancer: current evidence and clinical implications.

10. Retinoic acid-induced glandular differentiation of the oesophagus.

1. Association between NQO1 Pro187Ser polymorphism and esophageal cancer: a meta-analysis.

Review 2. Barrett esophagus: history, definition and etiopathogeny.